Although reduced clinical signs of arthritis and ocular disease following anti-IL-17 treatment suggest great therapeutic potential for the use of this antibody, our observations of retinal toxicity indicate the need to proceed cautiously. The gene discussed is IL17A; the disease is Arthritis.